Short answer
Exelon (EXC) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026.
Exelon Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue not disclosed in provided MD&A; net income $396M vs $391M YoY
- Adjusted operating earnings $438M vs $392M; diluted EPS $0.43 vs $0.39
- Best segment ComEd net income $249M, up $21M; worst PHI $109M, down $34M
- At-the-market issuance 8.7M shares, $382M proceeds for general corporate purposes
- Pending rate cases: Pepco Maryland approval expected third quarter 2026; requested increase $120M at 10.50% ROE
Risk Factors
- No risk-factors section provided; supplied text contains Items 5–6 and exhibits only
- New disclosure: CEO Calvin G. Butler, Jr. terminated his Rule 10b5-1 arrangement on June 9, 2026
- Trading-plan termination occurred before any shares were sold under its terms
- BGE issued 5.150% notes due 2033 and 6.050% notes due 2056 on May 22, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Exelon quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.